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Abstract
 
Interleukin (IL)-18 is a recently discovered cytokine that modulates both T helper type 1 (Th1)
and Th2 responses. IL-18 is elevated during acute graft-versus-host disease (GVHD). We in-
vestigated the role of IL-18 in this disorder using a well characterized murine bone marrow
 
transplantation (BMT) model (B6 
 
→
 
 B6D2F1). Surprisingly, blockade of IL-18 accelerated
acute GVHD-related mortality. In contrast, administration of IL-18 reduced serum tumor ne-
 
crosis factor (TNF)-
 
 
 
 and lipopolysaccharide (LPS) levels, decreased intestinal histopathology,
 
and resulted in significantly improved survival (75 vs. 15%, 
 
P
 
 
 
  
 
0.001). Administration of IL-18
attenuated early donor T cell expansion and was associated with increased 
 
Fas
 
 expression and
greater apoptosis of donor T cells. The administration of IL-18 no longer protected BMT re-
cipients from GVHD when 
 
Fas
 
 deficient (
 
lpr
 
) mice were used as donors. IL-18 also lost its abil-
ity to protect against acute GVHD when interferon (IFN)-
 
 
 
 knockout mice were used as do-
nors. Together, these results demonstrate that IL-18 regulates acute GVHD by inducing
enhanced 
 
Fas
 
-mediated apoptosis of donor T cells early after BMT, and donor IFN-
 
 
 
 is critical
for this protective effect.
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Introduction
 
IL-18 is a new member of the IL-1 family that was origi-
nally discovered as a factor that induces IFN-
 
 
 
 production
from T cells in the presence of IL-12 (1, 2). IL-18 is pro-
duced by a wide variety of cells such as macrophages (in-
cluding Kupffer cells, splenic, and alveolar macrophages),
microglia, human peripheral blood mononuclear cells, den-
dritic cells, keratinocytes, intestinal and airway epithelium,
osteoblasts, and adrenal corticocytes (3). IL-18 drives the
production of IFN-
 
 
 
, particularly in concert with IL-12,
from a number of cells in the immune system such as Th1
cells, nonpolarized T cells, NK cells, B cells, and dendritic
cells. However, IL-18 can also induce IL-4 and IL-13 pro-
duction in T cells, NK cells, mast cells, and basophils. Thus
IL-18 has the unique capacity to stimulate innate immunity
and both Th1- and Th2-mediated responses (3, 4). As dis-
cussed in a recent review by Nakanishi et al. (3), IL-18 has
been shown to play a protective role in host defense against
a variety of intracellular microbes such as 
 
Mycobacterium
avium
 
, 
 
Leishmania major
 
, and 
 
Cryptococcus neoformans
 
 and also
in the clearance of certain viral infections such as HSV and
influenza A. Furthermore, IL-18 may play a pathological
role in certain autoimmune diseases such as diabetes, rheu-
matoid arthritis, Crohn’s disease, and multiple sclerosis (3).
Acute GVHD, the major toxicity of allogeneic bone
marrow transplantation (BMT),
 
*
 
 is a complex process in-
volving dysregulation of inflammatory cytokine cascades
and distorted responses of donor cellular effectors, includ-
ing T cells, to host alloantigens (5). The Th1/Th2 polariza-
tion of T helper cell subsets may play an important role in
the development of acute GVHD (6). In some experimen-
tal models, a “cytokine storm” amplified by the Th1 phe-
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notype correlates with the development of acute GVHD
while a shift to Th2 polarization of donor cells inhibits
acute GVHD (7). The Th1/Th2 dichotomy as it relates to
GVHD, however, is not crisp; early administration of Th1
inducing cytokines, including IL-12, IFN-
 
 
 
, and IL-2 have
shown paradoxical ability to reduce the severity of acute
GVHD (8–10). Some studies have failed to demonstrate
beneficial effects of direct in vivo administration of Th2 cy-
tokines in preventing or treating acute GVHD (11, 12).
Furthermore, recent studies using donor mice deficient in
IFN-
 
 
 
, IL-4, or their molecular mediators (signal trans-
ducer and activator of transcription [STAT]4 or STAT6,
respectively) showed that despite the absence of these in
donor cells, acute GVHD can still occur (13–15).
IL-18 has been shown to prevent murine chronic
GVHD (16), but its role in acute GVHD in not known.
Serum concentrations of IL-18 are elevated in both clinical
and experimental acute GVHD (17, 18). For this reason,
and the fact that IL-18 can regulate the Th1/Th2 balance
in different ways depending on the context, we investi-
gated the role of IL-18 in modulating acute GVHD in a
well-characterized murine BMT model.
 
Materials and Methods
 
Mice.
 
Female C57BL/6 (B6, H-2
 
b
 
, CD45.2
 
 
 
), B6D2F1 (H-
2
 
b/d
 
, CD45.2
 
 
 
), B6.129S7-
 
IFN-
 
 
 
 
 
tm1Ts
 
(GKO, H-2
 
b
 
, CD45.2
 
 
 
),
B6.MRL-
 
TNF-rs6 
 
lpr
 
 (
 
lpr
 
, H-2b) mice were purchased from The
Jackson Laboratory. B6 CD45.1 (H-2b, CD45.1
 
 
 
) mice were
purchased from Frederick Cancer Research Facility. The age of
mice used for experiments ranged between 8 and 12 wk. Mice
were housed in sterilized microisolator cages and received filtered
water and normal chow or autoclaved hyper-chlorinated drinking
water for the first 3 wk post-BMT.
 
BMT.
 
Mice were transplanted according to a standard pro-
tocol described previously (19). Briefly, recipients received 13
cGy total body irradiation (TBI; 137Cs source), split into two
doses separated by 3 h to minimize gastrointestinal (GI) toxicity.
Bone marrow cells (5 
 
 
 
 10
 
6
 
) plus 2 
 
 
 
 10
 
6
 
 nylon wool–purified
splenic T cells from respective allogeneic or syngeneic donors
were resuspended (in 0.25 ml of Leibovitz’s L-15 media; GIBCO
BRL) and injected intravenously into recipients on day 0. For
engraftment experiments, CD45.1 (H-2b, CD45.1
 
 
 
 CD45.1)
animals were used as donors. Survival was monitored daily and
recipient’s body weights and GVHD clinical scores were mea-
sured weekly. Donor cell numbers were determined by examin-
ing the percentage of CD45.2
 
 
 
 cells in the recipient spleens at
different time points.
 
Assessment of Acute GVHD.
 
The degree of systemic acute
GVHD was assessed by a scoring system that incorporates five
clinical parameters: weight loss, posture (hunching), activity, fur
texture, and skin integrity, and that is more accurate than weight
loss alone as described previously (20). At the time of analysis,
mice from coded cages were evaluated and graded from 0 to 2 for
each criterion. A clinical index was subsequently generated by
summation of the five criteria scores (maximum index 
 
 
 
 10).
Transplanted mice were ear-punched and individual scores were
obtained and recorded on day 0 and weekly thereafter.
 
IL-18 Treatment.
 
Recombinant murine IL-18 was purchased
from RD Inc. and reconstituted in PBS. Mice were injected in-
traperitoneally with IL-18 (1 
 
 
 
g/day/mouse) on days 
 
 
 
2, 
 
 
 
1, 0,
 
1, and 2 (five injections total). Mice from the control groups re-
ceived only the diluent in a similar schedule. In the IL-18 block-
ade experiments rat anti–mouse IL-18 monoclonal antibody
(R&D Systems) was administered intraperitoneally (10 
 
 
 
g/day/
mouse), after reconstitution in PBS, on days –1, 0, 1, 2, and 3.
The control groups received rat IgG reconstituted and injected in
a similar fashion.
 
Carboxy Fluorescein Diacetate Succinimidyl Ester Labeling and
Analysis of In Vivo Expansion of Donor T Cells.
 
Fluorescent la-
beling of splenocytes was achieved as described (21). Briefly,
spleens from the donor mice were harvested and T cells were iso-
lated by nylon wool purification. Erythrocytes were lysed by hy-
potonic shock, and T cells were washed and resuspended at a
density of 10
 
6
 
 cells/ml in PBS. An equal volume of 2 
 
 
 
M car-
boxy-fluorescein diacetate succinimidyl ester (CFDASE; Molec-
ular Probes, Inc.) in PBS was added, and the cells were gently
mixed and incubated at 37
 
 
 
C for 15 min. Cells were then
washed, centrifuged, and the supernatant was removed. Un-
bound CFDASE, or the deacetylated form of carboxy fluorescein
diacetate succinimidyl ester (CFSE), was quenched by the addi-
tion of an equal volume of 10% FCS and incubated at 37
 
 
 
C for
30 min. Analysis of cells immediately following CFSE labeling
indicated a labeling efficiency that exceeded 99%. These CFSE
labeled cells were then resuspended in Leibovitz’s L-15 media
and infused into the recipient mice via the tail vein. After 3 d, the
recipient mice were killed and the spleens were harvested. Sple-
nocytes from three mice per group were pooled together and
were harvested from the interface after density centrifugation of
the spleen cells on Ficoll-Paque (Amersham Pharmacia Biotech).
Single cell suspensions were thus prepared for cell surface staining
and FACS
 
®
 
 analysis.
 
FACS
 
®
 
 Analysis.
 
FITC-conjugated mAbs to mouse
CD45.1 and PE-conjugated mAbs to Fas, CD4
 
 
 
, CD8
 
 
 
, and al-
lophycocyanin (APC)-conjugated mAbs CD3
 
 
 
 antigens were
purchased from BD PharMingen. For determining the extent of
donor T cell number and engraftment (anti-Ly 5.2 mAb) was
used as donor cell specific marker. The procedure was per-
formed as described previously (19). Briefly, cells were first in-
cubated with mAb 2.4G2 for 15 min at 4
 
 
 
C and then with the
relevant FITC-conjugated mAb for 30 min at 4
 
 
 
C. Finally, cells
were washed twice with PBS/0.2% bovine serum albumin and
fixed with PBS/1% paraformaldehyde. Three-color flow cytom-
etry was performed by using EPICS Elite ESP cell sorter (Beck-
man Coulter) and on FACSVantage™ SE cell sorter (Becton
Dickinson).
 
Analysis of Donor Cell Apoptosis.
 
Spleens from recipient mice
in some of the experiments were harvested 4 d after transplanta-
tion and stained with PE-conjugated CD45.1 and then washed
with 1
 
 
 
 PBS and then stained with FITC-conjugated annexin
(R&D Systems) in the dark for 15 min at room temperature in la-
beling buffer. Donor cell apoptosis was identified based on dou-
ble staining for CD45.1 and annexin.
 
ELISA.
 
Antibodies were purchased from BD PharMingen
and assays were performed according to the manufacturer’s pro-
tocol. Briefly, samples were diluted 1:2 to 1:5 and TNF-
 
 
 
 or
IFN-
 
 
 
 was captured by the specific primary mAb and detected by
horseradish peroxidase (TNF-) or biotin-labeled (IL-1) secondary
mAbs. Plates were read at 450 nm using a microplate reader
(Model 3550; Bio-Rad Laboratories). Recombinant mTNF-
 
 
 
and mIFN-
 
 
 
 (BD PharMingen) were used as standards for ELISAs.
Samples and standards were run in duplicate and the sensitivity of
the assays was 16 to 20 pg/ml for both cytokines, depending on
sample dilution. 
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Serum LPS Estimation.
 
The Limulus Amebocyte Lysate
(LAL) assay (Bio Whittaker) was performed according to the
manufacturer’s protocol to determine the endotoxin (LPS) con-
centration in serum. Briefly, serum samples were collected and
analyzed using pyrogen-free materials, diluted 10% (vol/vol) in
LAL reagent water, and heated to 70
 
 
 
C for 5 min to minimize
nonspecific inhibition. Samples were then incubated with equal
volumes of LAL for 10 min at 37
 
 
 
C and developed with equal
volumes of substrate solution for 6 min. The absorbance of the
assay plate was read at 405 nm using the same microplate reader
used in cytokine assays. Samples and standards were run in dupli-
cate and the lower limit of detection was 0.15 U/ml. All units
expressed are relative to the US reference standard EC-6.
 
Histology.
 
Formalin-preserved liver and small and large
bowel were embedded in paraffin, cut into 5-
 
 
 
m thick sections,
and stained with haematoxylin and eosin for histologic examina-
tion. Slides were coded without reference to prior treatment and
examined in a blinded fashion by a pathologist (C. Liu). A semi-
quantitative scoring system was used to assess the following ab-
normalities known to be associated with GVHD (22): small intes-
tine: villous blunting, crypt regeneration, loss of enterocyte brush
border, luminal sloughing of cellular debri, crypt cell apoptosis,
crypt destruction, and lamina propria lymphocytic infiltrate; co-
lon: crypt regeneration, surface coloncytes, colonocyte vacuoliza-
tion, surface colonocyte attenuation, crypt cell apoptosis, crypt
destruction, and lamina propria lymphocytic infiltrate. The scor-
ing system denoted 0 as normal, 0.5 as focal and rare, 1.0 as focal
and mild, 2.0 as diffuse and mild, 3.0 as diffuse and moderate, and
4.0 as diffuse and severe. Scores were added to provide a total
score for each specimen. After scoring the codes were broken and
data compiled.
 
Statistical Analysis.
 
The Mann-Whitney U test was used for
the statistical analysis of cytokine data, LPS levels, clinical scores,
weight loss, and histology, whereas the Wilcoxon rank test was
used to analyze survival data. 
 
P
 
 
 
 
 
 0.05 was considered statistically
significant.
 
Results
 
Administration of Anti–Mouse IL-18 mAb Exacerbates Acute
GVHD-related Mortality.
 
IL-18, a proinflammatory cy-
tokine, is elevated in acute GVHD in both murine and hu-
 
man studies (17, 18). We first examined the effect of neu-
tralizing IL-18 in vivo after allogeneic transplantation using
a C57BL/6 (B6, H2
 
b
 
) Æ C57BL/6 
 
 
 
 DBA2 (B6D2F1,
H-2
 
b/d
 
) BMT model of acute GVHD. Mice were trans-
planted as described in Materials and Methods. Groups of
syngeneic and allogeneic recipients received either 10 
 
 
 
g/
mouse/day of rat anti–mouse IL-18 mAb (R&D Systems)
or the control rat anti–mouse IgG antibody on days 
 
 
 
1, 0,
1, 2, and 3. Antibody was administered beginning on day
 
 
 
1 in order to obtain adequate systemic levels at the time
of transplant 24 h later, as in similar experiments that neu-
tralized IL-12 (23). Anti–IL-18 mAb was given until 3 d
after BMT because serum IFN-
 
 
 
 is increased at that time
and IL-18 expression is known to correlate with IFN-
 
 
 
 se-
cretion (18). Surprisingly, allogeneic BMT recipients in-
jected IL-18 mAb exhibited mortality more rapidly than
controls with 100% of animals dying by day 30, while the
control allogeneic group mice exhibited 35% survival at
the end of 50 d observation period, as shown in Fig. 1 A
(
 
P
 
 
 
  
 
0.05). All allogeneic BMT recipients showed clinical
features of acute GVHD at the time of death. Mice receiv-
ing syngeneic BMT (F1 
 
→
 
 F1) and anti–IL-18 mAb
showed 100% survival, thereby ruling out any nonspecific
toxicity of the therapy.
The increase in acute GVHD in the anti IL-18 mAb
group was associated with greater GI damage as measured
by increased systemic translocation of LPS and higher levels
of serum TNF-
 
 
 
 (Fig. 1, B and C). Damage to the GI tract
during acute GVHD from cytokines such as TNF-
 
 
 
 cause
increased leakage of inflammatory stimuli (including LPS)
into the systemic circulation which then triggers additional
TNF-
 
 
 
 production, making the GI tract a pivotal target
organ in the pathophysiology of this disorder (5). Greater
levels of LPS and TNF-
 
 
 
 were also associated with higher
histopathologic scores of GI pathology for acute GVHD
(data not shown). The administration of anti–IL-18 mAb in
syngeneic BMT recipients did not increase the serum levels
of either LPS or TNF-
 
 
 
 concentrations, ruling out non-
specific effects of IL-18 neutralization. Furthermore, the
Figure 1. IL-18 blockade exacerbates
acute GVHD mortality and increases serum
LPS and TNF-  B6D2F1 mice were trans-
planted as described in Materials and Meth-
ods with 5   106 BM cells and 2   106
NWP T cells from B6 allogeneic donors
after 1,300 cGy TBI and were injected in-
traperitoneally with 10  g/mouse/day of
anti–mouse IL-18 mAb ( , n   15) or the
control, rat IgG, intraperitoneally ( ; n  
15) for 5 d (day  1 to day  3). Recipients
of the syngeneic B6D2F1 cells ( , n   10)
were treated with the same dose and sched-
ule of anti–mouse IL-18 mAb. One of two
similar experiments is shown. (A) IL-18 blockade exacerbated acute GVHD mortality. P   0.04,   vs.  , by Wilcoxon rank test. Syngeneic mice exhib-
ited 100% survival during the 50-d observation period. (B) Mice were transplanted as in panel A and serum was obtained by performing retro-orbital
venous puncture on day 7 post-BMT. Syngeneic plus anti–IL-18 mAb (white bar), allogeneic plus control IgG (black bar), and allogeneic plus anti–IL-18
mAb (dotted bar). *P   0.04, dotted bar vs. solid bar. Data represent the mean   SE (n   4/group). One of three representative experiments is shown. (C)
Mice were transplanted as in panel A and serum was obtained as in B. Syn plus anti–IL-18 mAb (white bar), allo plus control IgG (black bar), and allo
plus anti–IL-18 mAb (dotted bar). *P   0.05, dotted bar vs. black bar. Data represent the mean   SE (n   4/group). One of three representative exper-
iments is shown.1436 IL-18 Modulates Acute GVHD
mice that received anti–IL-18 mAb demonstrated dimin-
ished levels of serum IFN-  compared with the control
group (930   55 pg/ml vs. 2,555   294 pg/ml, P   0.03),
demonstrating the in vivo efficacy of anti–IL-18 mAb in
regulating the secretion of IFN-  after allogeneic BMT.
However allogeneic recipients that received anti–IL-18
mAb had significantly greater number of total donor T and
CD4 cells in their spleens during the first week when com-
pared with the control group (Table I), suggesting that
neutralization of IL-18 amplified the donor T cell response
to host alloantigens.
Administration of IL-18 Early after BMT Reduces Acute
GVHD Mortality, Morbidity, and Histopathology. In light
of these unexpected effects of IL-18 neutralization, we
next studied the effect of exogenous administration of IL-
18 itself on the severity of acute GVHD. Recombinant
murine IL-18 (IL-18; RD Inc.) was administered to BMT
recipients intraperitoneally for 5 d from day  2 to  2;
control mice received identical injections of PBS. This
dose of rmIL-18 was chosen because it was effective at
modulating IFN-  secretion (24). Preliminary experiments
using different dosing schedules (day 0 only, day 0 to  2,
day –2 to 0) that were successful for other cytokine modu-
lators of GVHD (25, 26), had no effect on GVHD mortal-
ity (data not shown). As shown in Fig. 2 A, animals re-
ceiving IL-18 from day –2 to  2 showed significant
improvement in survival at day 50 (75 vs. 15%, P   
0.001). The IL-18–treated animals also displayed signifi-
cantly less clinical acute GVHD than allogeneic controls
(Fig. 2 B, P   0.05). All mice in both groups displayed
complete donor hematopoietic chimerism as determined
by FACS® analysis (data not shown) ruling out mixed chi-
merism as a cause for reduced GVHD.
We next examined the bowel for histologic changes of
acute GVHD using a semiquantitative index of GI damage
(see the Materials and Methods). Allogeneic BMT recipi-
ents treated with IL-18 demonstrated significantly less GI
tract pathology and reduced levels of serum LPS and TNF- 
(Fig. 3, A–C). These results are consistent with our pre-
vious observations that GI tract damage of acute GVHD is
associated with increased translocation of LPS into the sys-
temic circulation and also with significantly greater serum
levels of TNF-  (5). Thus early administration of IL-18
significantly prevented acute GVHD by all clinical, patho-
logic, and biochemical indices examined.
IL-18 Alters Donor T Cell Expansion. The expansion of
donor T cells caused by anti–IL-18, combined with the
clear effects of IL-18 in reducing GVHD, suggested that
IL-18 might exert its protective effect through alteration of
donor T cell response to host antigens. We first investi-
gated whether IL-18 administration dampened the kinetics
of donor T cell expansion in the recipient spleens in the
Table I. Effects of IL-18 Administration or Neutralization on Donor T Cell Expansion
Donor splenocytes (  106)
Day  5 Day  7
Treatment CD3 CD4 CD8 CD3 CD4 CD8
Control 6.4   1.2 3.12   0.7 2.3   0.1 16.2   3.2 6.8   1.1 7.1   2.0
Anti–IL-18 mAb 9.8   0.6a 5.4   1a 2.9   1.2 26.2   4.1a 15.6   3.8a 10.8   2.9
IL-18 3.5   1.0b 1.3   0.4b 1.9   0.05 8.8   1.4b 3.4   0.9b 3.9   1.3
B6D2F1 mice were irradiated, transplanted with BM and T cells from B6 Ly5.2 donors and treated with anti–IL-18 mAb or the control Ab (as in
Fig. 1) or IL-18 (as in Fig. 2). Splenocytes from three mice per group were pooled and analyzed for donor T cell expansion on days  5 and  7 post-
BMT by two-color flow cytometry for expression of donor marker (CD45.1 ) and CD3 , CD4 , and CD8  cells. Data represent average of three
mice per group mean   SE from two or three experiments.
aP   0.05 vs. control.
bP   0.04 vs. control.
Figure 2. Exogenous administration of IL-18 re-
duces acute GVHD mortality and morbidity.
B6D2F1 mice were given 1,300 cGy of TBI and
transplanted with 5   106 BM cells and 2   106
NWP T cells from B6 donors and injected intraperi-
toneally with 1  g/mouse/day of IL-18 ( ; n   20)
or diluent ( ; n   20) on days –2 to  2. Recipients
of the syngeneic B6D2F1 cells ( , n   6) received
the same dose and schedule of IL-18. Data from two
similar experiments are combined. (A) Percent sur-
vival after BMT.   vs.  , P  0.0008 by Wilcoxon
rank test. (B) Animals were scored for clinical
GVHD as described in Methods.   vs.  , P   0.05
by Mann-Whitney U test from day 14 to 42.1437 Reddy et al.
first 5 d after BMT. Consistent with our hypothesis, IL-18
treatment markedly reduced the donor T cell expansion as
shown in Fig. 4 A. Given that acute GVHD in this donor –
recipient strain combination is predominantly driven by
CD4  donor T cells (14) we also investigated the kinetics
of CD4 and CD8 expansion. IL-18 administration reduced
the expansion primarily of the CD4 T cell subset (Table I).
CFSE analysis confirmed this inhibition by IL-18 of splenic
donor T cells undergoing more than two cell divisions
(Fig. 4 B).
IL-18 Causes Donor T Cell Apoptosis by Upregulating
Fas. Reduced donor T cell expansion could be due to ei-
ther lack of stimulation or increased apoptosis of activated
cells (activation-induced cell death [AICD]). Fas, a member
of TNF-R receptor family, is known to mediate AICD
(27) and hence we next investigated whether IL-18 in-
duced Fas expression on donor T cells. Spleens from the
transplanted mice were harvested on day 4 and donor cells
were analyzed by flow cytometry for annexin staining as a
measure of apoptosis. As shown in Table II, IL-18–treated
mice showed a greater percentage of donor cell apoptosis.
Using three-color flow cytometry (FCM) analysis, we next
determined that the apoptosis is associated with increased
Fas expression on donor T cells (CD 45.1 /CD3 ) in the
IL-18–treated group compared with the control group
(Table II).
To determine the functional relevance of the increased
Fas expression and AICD by donor T cells in IL-18–medi-
ated protection from GVHD we tested whether IL-18
would protect animals if the donor cells lacked Fas. When
Fas-deficient (lpr, H-2b) mice were used as donors, all re-
cipient mice died whether or not they received IL-18,
whereas IL-18 protected recipients of the wild-type do-
nors, as seen previously (Fig. 5 A). Furthermore, donor T
cell expansion was not suppressed by rmIL-18 administra-
tion when lpr mice were used as donors (3.9   0.4   106
Figure 3. IL-18 treatment reduces the pathological
and biochemical indices of acute GVHD of the GI
tract. B6D2F1 mice were transplanted as in Fig. 2,
animals were killed, and GI tract and serum were ob-
tained for analysis as described in Materials and
Methods. (A) Coded slides were scored for patholog-
ical damage, as described in Materials and Methods,
on day 7 post-BMT. Recipients of allogeneic BMT
plus diluent (black bar, n   4) or IL-18 (dotted bar,
n   4) and recipients of syngeneic plus IL-18 (white
bar,  n    4) are shown. *P    0.03 vs. IL-18 allo
group. Data (mean   SE) from one of two similar
experiments are shown. (B) Serum LPS levels are re-
duced after IL-18 treatment. Controls (black bar) vs. IL-18–treated recipients (dotted bar), *P   0.05. Data are from one of two similar experiments. (C)
Serum TNF-  levels. Controls (black bar) vs. IL-18–treated recipients (dotted bar), P   0.04.
Figure 4. IL-18 treatment reduces early donor T cell expansion. Re-
cipient mice were transplanted as in Fig. 2. (A) Splenocytes were har-
vested from the recipients at each time point as shown (n   4/per group)
and labeled with anti-CD3 PE and anti-CD45.1 FITC. The number of
donor T cells (CD45.1  CD3 ) were determined (Allo   control,   vs.
Allo   IL-18,  ) at various time points, from days 2 to 5 post-BMT. *P  
0.03. Recipients of syngeneic BMT ( ) demonstrated lower numbers of
donor T cells at all time points. Data from one of three similar experi-
ments is shown. (B) Nylon wool purified B6Ly5.2 donor T cells were la-
beled with CFSE as described in Materials and Methods and injected into
B6D2F1 recipients after 1,300 cGy TBI. Splenocytes were harvested and
pooled (n    3/group) on day 3 post-BMT, and labeled with anti-
CD45.1 APC. The percent of donor cells (CFSE  CD45.1 ) undergoing
cell expansion was determined. Fewer percentage of donor cells under-
went beyond two cell divisions in IL-18–treated group than allogeneic
controls, 7 vs. 28%. One of three representative experiments is shown.
Table II. Donor T Cell Apoptosis and Fas Expression
Percent Fas  Percent Annexin 
Syn plus IL-18 29   49     3
Allo plus control 48   7 24   4
Allo plus IL-18 64   5a 44   6a
B6D2F1 mice were irradiated, transplanted, and treated with IL-18 or
the diluent as in Fig. 2. Splenocytes were pooled from four mice per
group and analyzed on day 4 post-BMT by three-color flow cytometry
for expression of Fas, CD45.1 , and CD3  cells. Gates were set for
CD45.1 CD3  (donor) cells and percentage of cells expressing Fas or
annexin was determined. Data represent mean    SE from three
experiments.
aP   0.05 allo plus IL-18 versus allo plus control.1438 IL-18 Modulates Acute GVHD
vs. 4.1   0.8   106 on day  3). Thus, IL-18 protected
mice against acute GVHD by increasing Fas-mediated do-
nor T cell apoptosis early after BMT.
The Beneficial Effect of IL-18 on Acute GVHD Is Dependent
on Donor-derived IFN- . IFN-  has been shown to be im-
portant in regulating the death of activated T lymphocytes
(28) and it is important in mediating the biological effects
of IL-18 (2). When serum levels were analyzed after BMT,
IL-18 treatment resulted in higher IFN-  levels than con-
trols on days 2 and 3; levels on day 4 were equivalent be-
tween the groups (data not shown). In a final set of experi-
ments we evaluated the role of donor-derived IFN-  in
mediating the effect of IL-18 in our model of acute GVHD
using IFN-  knockout (GKO) mice as donors. All mice re-
ceiving GKO donor cells died irrespective of IL-18 treat-
ment (Fig. 5 B). Analysis of T cell expansion (day  3)
demonstrated equivalent expansion of GKO donor T cells
in the recipient spleen irrespective of IL-18 treatment
(4.9   0.7   106 vs. 5.8   0.2   106). Thus, the ability of
IL-18 to cause donor T cell apoptosis and reduce the sever-
ity of acute GVHD depends, at least in part, upon donor-
derived IFN- .
Discussion
To determine the role of IL-18 in acute GVHD we
used a well-defined irradiated murine BMT model, B6
(H2b) → B6D2F1 (H-2b/d) in which the host and donor
differ at both MHC class I, MHC class II, and multiple
minor histocompatibility antigens. Administration of anti–
IL-18 mAb increased acute GVHD. This was surprising
because IL-18 is elevated during acute GVHD (17, 18)
and is known to induce Th1 differentiation and cytotoxic
T lymphocyte function (2), both of which have been im-
plicated in the pathogenesis of acute GVHD. Blockade of
endogenous IL-18 was associated with greater expansion
of donor T cells and an increase in serum levels of TNF- .
More interestingly, injection of IL-18 early in BMT to
the recipients reduced acute GVHD and caused a decrease
in serum TNF-  and LPS levels, which correlate with the
severity of acute GVHD in this model (19). The donor,
recipient strain combination used in our experiments is
characterized by “hybrid resistance” mediated by host NK
cells and can result in graft rejection (29). IL-18 is known
to enhance NK cell activity (30) and might therefore in-
crease the risk of graft rejection. The protective effect of
IL-18 treatment is not, however, due to graft rejection
because IL-18 treated recipients showed complete donor
hematopoietic chimerism.
IL-18 administration did inhibit early expansion of do-
nor T cells, blunting and delaying the proliferative re-
sponses of donor T cells to host alloantigens. Interestingly,
IL-18 caused a reduction in expansion of both CD4 and
CD8 subsets, albeit the effect on CD8 T cells was not sta-
tistically significant (Table I). The effect of IL-18 on effec-
tor CD8 cells has been shown to be CD4 dependent (31),
hence it remains to be determined whether IL-18 attenu-
ates acute GVHD in a CD8-dependent murine BMT
model. We further observed that IL-18 treatment caused
greater apoptosis and increased Fas expression on donor T
cells in recipient spleens. In addition to Fas, IL-18 also in-
creased CD25 and CD69 expression on donor T cells early
after BMT (data not shown) thus suggesting an increased
activation of donor T cells with IL-18 treatment. The
functional importance of Fas on donor T cells was con-
firmed when IL-18 did not protect recipients of Fas /  (lpr)
donors cells from acute GVHD. Thus, blocking Fas-medi-
ated apoptosis by using lpr donors inhibited peripheral T
cell deletion induced by administration of IL-18.
IFN-  plays an important role in regulating the death of
activated T lymphocytes (28) and is known to be critical in
mediating the biological effects of IL-18 (2). When IFN-
 –deficient mice were used as donors, recipients were not
protected by IL-18 from GVHD mortality. Thus IL-18–induced
protection against GVHD requires IFN-  production by
allogeneic donor cells. Donor-derived IFN-  also appears
to play a critical role in the inhibition of early donor T cell
proliferation by IL-18 as measured by CFSE staining (data
not shown). Although our study cannot rule out the possi-
bility that host-derived IFN-  also contributes to AICD of
donor T cells, our data indicates that host-derived IFN- 
alone cannot mediate the protective effects of IL-18. How-
ever, it is possible that the GKO and wild-type T cells may
differ in their susceptibility to apoptosis and kinetics of ex-
pansion (32) and hence may induce GVHD via distinct
mechanisms. Therefore, the differential effect of IL-18 on
GVHD in the two groups may reflect the presence of dis-
tinct effector mechanisms in the presence and absence of
donor derived IFN- .
Similar inhibition of GVHD has been noted however by
administration of other Th1 cytokines such as IFN- , IL-2,
and IL-12 (8–10). IL-18 administration appears to impart
some of its beneficial effects in a manner similar to IL-12,
e.g., perturbation of early donor T cell expansion and re-
Figure 5. Requirement of Fas expression and IFN-  production by do-
nor T cells for IL-18–mediated GVHD protection. (A) B6D2F1 mice
were transplanted as in Fig. 2 with either B6D2F1 (syn) donors ( , n   6)
or lpr (H2b;  , n   8 and  , n   8) or wild-type B6 donors ( , n   8
and  , n   8). Transplanted mice received IL-18 (  and  ) or the con-
trol diluent (  and  ) from day –2 to  2. Results from one of two simi-
lar experiments is shown.   vs.   P   0.0008;   vs.  , P   0.1;   vs.
 , P   0.001. (B) B6D2F1 mice were transplanted as in Fig. 2 with either
B6D2F1 donors ( , n   6) or B6.129S7-IFN-gtm1Ts (H2b;  , n   8 and
O, n   8) or wild-type B6 donors ( , n   8 and  , n   8). Transplanted
mice received IL-18 (  and  ) or the control diluent (  and  ) from day
–2 to  2.   vs.   P   0.001;    vs. O P   0.07;   vs.   P   0.0009.1439 Reddy et al.
quirement of Fas expression and IFN-  production by do-
nor cells (8, 14, 33). IL-18 and IL-12 differ in several re-
spects, however. Blockade of IL-18 increased GVHD
related mortality unlike IL-12 blockade (23); IL-18 treat-
ment caused a decrease in serum TNF-  but IL-12 treat-
ment did not (33). Finally, the biphasic effect on serum
IFN-  levels reported with IL-12 treatment (8) was not
observed with IL-18 treatment. It has also been demon-
strated that IL-12 from both donor and recipient sources
contribute to increased severity of acute GVHD (34). Al-
though a recent study suggests that the elevated levels of se-
rum IL-18 observed after allogeneic BMT is likely to be
host derived (35), the study did not address its role in
GVHD pathophysiology. Future experiments will deter-
mine if host- or donor-derived IL-18 is critical and
whether there is a synergistic benefit by administering IL-
12 and IL-18 early in BMT.
IL-18 has been shown to prevent murine chronic
GVHD by inducing IFN-  production from lymphocytes
and thereby inhibiting IgG1 and IgE production (16, 36).
But the increase in serum levels of IL-18 in acute GVHD
(17, 18) initially suggested that perhaps this protein would
amplify cytokine dysregulation that characterizes this disor-
der. Clearly, our data demonstrated that IL-18 does not
play such a role and rather suggests that the increased pro-
duction of IL-18 may be a regulatory response to an ag-
gressive systemic alloreaction. The increase in apoptosis of
donor T cells in the control recipient of allogeneic (com-
pared with syngeneic) BMT suggests that an attempt at
such regulation may indeed occur normally during a
GVHD reaction, and that there is a natural contraction of
the donor T cell response to host alloantigens that follows
immediately upon its rapid activation. This contraction re-
quires Fas expression and IFN-  production by donor T
cells leading to peripheral deletion by donor T cell “fratri-
cide”. Peripheral deletion of allo-reactive T cells can lead
to tolerance (37). Thus, IL-18 when given early in BMT
enhances this peripheral deletion of donor T cells and re-
duces GVHD as can other Th1 inducing cytokines such as
IL-12 and Th1 cytokines such as IFN-  and IL-2 (8–10).
Administration of Th1-inducing cytokines, such as IL-12,
can accelerate acute GVHD when administered later dur-
ing the cytokine cascade (38); it remains to be determined
whether delayed administration of IL-18 behaves in a simi-
lar detrimental fashion in this model. Thus, Th1 cytokines
can play a dual role in acute GVHD, as effector cytokines
that can damage GVHD target tissues and amplify produc-
tion of inflammatory cytokines (5, 7) and also as regulators
of alloreactive T cells that leads to their deletion by apopto-
sis early after BMT. The timing of administration and the
systemic production of any given cytokine may therefore
be critical to the eventual outcome of acute GVHD, and
improved understanding of interactions between cells and
cytokines may offer new therapeutic opportunities to mod-
ulate this serious and complex clinical disorder.
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